SET and MYND domain-containing protein 3 inhibits tumor cell sensitivity to cisplatin

Cisplatin resistance has been a major factor limiting its clinical use as a chemotherapy drug. The present study aimed to investigate whether SET and MYND domain-containing protein 3 (SMYD3), a histone methyltransferase closely associated with tumors can affect the sensitivity of tumors to cisplatin...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Lei, Xu, Man-Li, Wang, Chang, Dong, Qing-Qing, Miao, Zhi, Chen, Xiao-Ying, Wang, Nan, He, Hong-Peng, Zhang, Tong-Cun, Luo, Xue-Gang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7114722/
https://www.ncbi.nlm.nih.gov/pubmed/32269620
http://dx.doi.org/10.3892/ol.2020.11465

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7114722/
https://www.ncbi.nlm.nih.gov/pubmed/32269620
http://dx.doi.org/10.3892/ol.2020.11465

Ejemplares similares